Immix Biopharma Executives Bulk Up Holdings: Nancy Chang’s 6,250‑Unit RSU Purchase Signals Strong Confidence in Upcoming Clinical Milestones
Immix Biopharma insiders, led by senior exec Chang Nancy T, buying RSUs signals confidence in its oncology pipeline and potential valuation rebound.
4 minutes to read